Page 12 - Avidity Partners News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mirum to acquire all of Travere’s rights and assets related to Cholbam® and Chenodal® Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential sales-based milestones Mirum announces concurrent private placement of $210 million, funding upfront payment Expands Mirum’s leadership in rare liver disease with two commercial products and a near-term Phase 3 label expansion opportunity Advances Travere’s strategy to deliver new treatment standards from its pipeline of innovative medicines for rare diseases and strengthens financial foundation Mirum to host conference call today, July 17, 2023, at 8:30 a.m. ET/5:30 a.m. PT

United statesChris peetzDunn crutcherLatham watkinsTravere therapeutics incFrazier life sciencesMirum pharmaceuticals incMorgan stanleySofinnova investments incMirum pharmaceuticalsTravere therapeuticsAvidity partnersLongitude capitalSofinnova investmentsGhost conferenceBile acid transporters